Tag - KTTA

Developments

FDA clears Pasithea’s IND application for Phase 2 trial of PAS-004 in cNF

Pasithea Therapeutics (NASDAQ: KTTA) has announced that the FDA has cleared its Investigational New Drug (IND) application for a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with NF1...

November 3, 2026

Developments

Pasithea reports updated Phase 1 data for PAS-004 in solid tumors

Pasithea Therapeutics (NASDAQ: KTTA) has announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated population of...

October 23, 2026

Developments

Pasithea reports positive interim Phase 1 cancer study data

Pasithea Therapeutics (NASDAQ: KTTA) has announced updated interim safety and clinical activity data from its ongoing first-in-human trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a...

June 30, 2026

Developments

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Pasithea Therapeutics (NASDAQ: KTTA) announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004...

September 8, 2025

Developments

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...

September 26, 2024

Tag - KTTA

FDA clears Pasithea’s IND application for Phase 2 trial of PAS-004 in cNF

Pasithea reports updated Phase 1 data for PAS-004 in solid tumors

Pasithea reports positive interim Phase 1 cancer study data

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Subscribe